News – Page 5 – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

2024.06.202025.12.01 / New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements previously announced strategic corporate part ...

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage

2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Earthquakes, investing in drugs, and how to be decent in Venture Capital.

2024.04.232024.04.24 / Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series. The discussion include ...

Theolytics

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

2024.04.172026.03.05 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...

Beyond fundraising: how do venture capitals build early-stage biotechs?

2024.02.292025.12.02 / It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant rol ...

ARTHEx biotech

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

2024.02.282024.05.13 / -ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.

2024.02.132025.12.01 / Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Poten ...

Sound Bioventures 2023 year in review

2024.01.302025.12.02 / A busy year with the final close of Sound Bioventures Fund I 2023 was a busy year for Sound Bioventures with the final close of Sound Bioventures Fund I taking the final total capital commitments ...

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252025.12.01 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

2024.01.092024.05.13 / Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing a New Approach ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year

2024.01.042024.05.13 / Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory Role Additional Promotions Include Dr. Andre Hoekema to Board Chair, Dr. Maria Nichol to Chief Business Offic ...